Skip to main content
Have a personal or library account? Click to login
The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics Cover

The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Open Access
|Oct 2019

References

  1. Plana JC Galderisi M Barac A Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Eur Heart J Cardiovasc Imaging 2014 Oct 15 10 1063 93
  2. Cardinale D Colombo A Bacchiani G Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy Circulation 2015 Jun 2 131 22 1981 8
  3. Ewer MS Vooletich MT Durand JB Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 2005 Nov 1 23 31 7820 6
  4. Eschenhagen T Force T Ewer MS Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 2011 Jan 13 1 1 10
  5. Lang RM Bierig M Devereux RB Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 2005 Dec 18 12 1440 63
  6. Hamza A Tunick PA Kronzon I Echocardiographic manifestations of complications of radiation therapy Echocardiography 2009 Jul 26 6 724 8
  7. Edoute Y Haim N Rinkevich D Brenner B Reisner SA Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients Am J Med 1997 Mar 102 3 252 8
  8. Casey DJ Kim AY Olszewski AJ Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma Am J Hematol 2012 May 87 5 521 4
  9. Palaskas N Morgan J Daigle T Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors Am J Cardiol 2019 Apr 15 123 8 1351 7
  10. Badano LP Boccalini F Muraru D Current clinical applications of transthoracic three-dimensional echocardiography J Cardiovasc Ultrasound 2012 Mar 20 1 1 22
  11. Armstrong GT Plana JC Zhang N Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging J Clin Oncol 2012 Aug 10 30 23 2876 84
  12. Thavendiranathan P Grant AD Negishi T Plana JC Popović ZB Marwick TH Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy J Am Coll Cardiol 2013 Jan 8 61 1 77 84
  13. Thavendiranathan P Poulin F Lim KD Plana JC Woo A Marwick TH Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review J Am Coll Cardiol 2014 Jul 1 63 25 Pt A 2751 68
  14. Negishi K Negishi T Hare JL Haluska BA Plana JC Marwick TH Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity J Am Soc Echocardiogr 2013 May 26 5 493 8
  15. Ali MT Yucel E Bouras S Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines J Am Soc Echocardiogr 2016 Jun 29 6 522 527.e3
  16. Risum N Ali S Olsen NT Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults J Am Soc Echocardiogr 2012 Nov 25 11 1195 203
  17. American College of Cardiology [Internet] Washington, DC American College of Cardiology 2018 Global Longitudinal Strain for LV Function; 2018 Aug 10 [cited 2019 Sep 11]. Available from: https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2018/08/10/11/01/assessment-of-left-ventricular-global-longitudinal-strain
  18. Schwartz RG McKenzie WB Alexander J Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography Am J Med 1987 Jun 82 6 1109 18
  19. Bellenger NG Burgess MI Ray SG Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000 Aug 21 16 1387 96
  20. Huang H Nijjar PS Misialek JR Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance J Cardiovasc Magn Reson 2017 Mar 24 19 1 34
  21. Walker J Bhullar N Fallah-Rad N Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 2010 Jul 20 28 21 3429 36
  22. The clinical role of magnetic resonance in cardiovascular disease. Task Force of the European Society of Cardiology, in collaboration with the Association of European Paediatric Cardiologists Eur Heart J 1998 Jan 19 1 19 39
  23. Grothues F Smith GC Moon JC Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy Am J Cardiol 2002 Jul 1 90 1 29 34
  24. Armstrong AC Gidding S Gjesdal O Wu C Bluemke DA Lima JA LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice JACC Cardiovasc Imaging 2012 Aug 5 8 837 48
  25. Tham EB Haykowsky MJ Chow K Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling J Cardiovasc Magn Reson 2013 Jun 10 15 48
  26. Neilan TG Coelho-Filho OR Pena-Herrera D Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines Am J Cardiol 2012 Dec 1 110 11 1679 86
  27. Mahmood SS Fradley MG Cohen JV Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol 2018 Apr 24 71 16 1755 64
  28. Cardinale D Sandri MT Colombo A Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 2004 Jun 8 109 22 2749 54
  29. Cardinale D Colombo A Torrisi R Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 2010 Sep 1 28 25 3910 6
  30. Sawaya H Sebag IA Plana JC Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab Circ Cardiovasc Imaging 2012 Sep 1 5 5 596 603
  31. Ky B Putt M Sawaya H Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 2014 Mar 4 63 8 809 16
  32. Fallah-Rad N Walker JR Wassef A The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 2011 May 31 57 22 2263 70
  33. Putt M Hahn VS Januzzi JL Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab Clin Chem 2015 Sep 61 9 1164 72
  34. Pourier MS Kapusta L van Gennip A Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines Clin Chim Acta 2015 Feb 20 441 29 32
  35. Upadhyay A Lopez-Mattei J Kim P Diagnostic performance of high sensitivity troponin in cancer patients J Am Coll Cardiol 2019 Mar 73 9 Suppl 1 209
  36. Okumura H Iuchi K Yoshida T Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity Acta Haematol 2000 104 4 158 63
  37. Dodos F Halbsguth T Erdmann E Hoppe UC Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults Clin Res Cardiol 2008 May 97 5 318 26
  38. Eliaz I The Role of Galectin-3 as a Marker of Cancer and Inflammation in a Stage IV Ovarian Cancer Patient with Underlying Pro-Inflammatory Comorbidities Case Rep Oncol 2013 Jul 3 6 2 343 9
  39. Ky B Putt M Sawaya H Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 2014 Mar 4 63 8 809 16
  40. Cardinale D Colombo A Lamantia G Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 2010 Jan 19 55 3 213 20
  41. Zamorano JL Lancellotti P Rodriguez Muñoz D ESC Scientific Document Group 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J 2016 Sep 21 37 36 2768 2801
  42. Armenian SH Lacchetti C Barac A Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2017 Mar 10 35 8 893 911
  43. Cameron D Piccart-Gebhart MJ Gelber RD Herceptin Adjuvant (HERA) Trial Study Team 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 2017 Mar 25 389 10075 1195 1205
  44. Zarifa A Albittar A Kim PY Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy Curr Opin Cardiol 2019 Jul 34 4 441 450
Language: English
Page range: 258 - 266
Published on: Oct 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2019 Ali Agha, Abdulrazzak Zarifa, Peter Kim, Cezar Iliescu, Greg Gladish, Saamir Hassan, Nicolas Palaskas, Jean B. Durand, Yang Lu, Juan Lopez-Mattei, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.